Searched for
SUPRIYA LIFESCIENCE RESULTS
Supriya Lifescience shares surge 17% on strong Q4 earnings; PAT rises 47% YoYSupriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surgin...- 36 smallcaps shine with double-digit gains as fag-end rally help markets recoup weekly lossesIndian equity markets rebounded strongly this week, with the Sensex closing nearly 2% higher. Small-cap stocks led the rally, with Banco Pr...
- Pharma sector: Turnaround for good, 6 small and mid cap pharma stocks with upside potential of up to 32%While it might not have been making it headline, the pharmaceutical sector or commonly called as pharma has come through a tough period due...
- Supriya Lifesciences Q3 Results: Net profit triples to Rs 30 croreRevenues rose 33% YoY to Rs 140 crore in Q3FY24. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for Q3FY24 almost ...
- For investors with slightly higher risk appetite: 4 smallcap stocks with upside potential of up to 41%After a phase of correction the small cap stocks segment has been able once again inch upward. Lower oil prices, softer inflation numbers a...
- New tailwinds emerge! 5 midcap pharma stocks with upside potential of up to 37%If one looks at corporate announcements, a large number of small and mid-caps pharma companies are announcing one or the other thing either...
- For risk takers: 8 smallcap stocks from different sectors with upside potential of up to 44%Even as the stock market corrects, small and midcap stocks are refusing to leave the party. On a number of days the breadth of the small ca...
- Finally out of the woods? 5 small and midcap pharma stocks with an upside potential of up to 23%Pharma as a sector, both in terms of business and stocks price performance has been under pressure for a very long time. Some time USFDA is...
- ETMarkets Fund Manager Talk: Divam Sharma of Green Portfolio tells why he’s bullish on these 6 mid- & smallcap names“Despite being small and midcaps, these are fundamentally strong companies which are high on corporate governance, growth prospects and yet...
- On path to recovery: 4 small- and mid-cap pharma stocks with upside potential up to 27%Pharma as a sector has been under pressure for a very long time. However, some of the small and mid sized Indian pharma companies which are...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 25%As broader market indices witness minor consolidation, which normally happens when they are close to all time high as some resistance is bo...
- On a path to recovery: 4 small and mid cap pharma stocks with an upside potential up to 25 %Pharma as a sector has been under pressure for a very long time. However, some of the small and mid sized Indian pharma companies which are...
- Opportunities amid volatility; 6 smallcaps with high ROE and ROCE have upside scope of up to 36%As the nifty continues to move upward, small caps are joining the party. Even on days when select stocks are bringing nifty under pressure,...
- On a path to recovery: 4 small pharma stocks with an upside potential of up to 27%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mi...
- Top picks of the week: 4 stocks with consistent score improvement and upside potential of more than 52%In the two months of the volatile phase with a bearish bias, market breadth has been the biggest casualty. Even in such times during this p...
- Pre-IPO lock-in of 14 companies to expire in 2022; analysts remain positive on major playersThe list includes startup players and traditional businesses from financial services, industrial mining, speciality chemicals, pharmaceutic...
- Day’s biggest gainers & losers: BGR energy hits upper circuit, Dilip Buildcon tanks2021 has been a strong year for equities where largecap benchmarks delivered 21-23 per cent returns to investors, and second-rung benchmark...
- Supriya Lifescience to sustain 40% plus EBITDA margin going forward: Saloni Wagh“Our business model is completely derisked and the company has very strong fundamentals. Whatever percentage of growth we have seen in the ...
- F&O expiry, FPI selling among key factors that may guide market this weekForeign investors continued their unabated selling last week, a trend seen in the last three months. They have withdrawn Rs 17,825 crore so...
- Forget May 16, mkt-savvy politicos already winner as scrips upOutcome of their performance will be known on May 16 but scores of LS aspirants are sitting on hefty returns courtesy their investments in ...
Load More
